A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

Wang Yun; Y Wang; Jorn Herrstedt; Hanne Havsteen; Rene DePoint Christensen; DePoint R Christensen; Mansoor Raza Mirza; Bente Lund; Johanna Mäenpää; Gunnar Kristensen

doi:10.1186/1471-2407-14-937

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

Wang Yun, Y Wang, Jorn Herrstedt, Hanne Havsteen, Rene DePoint Christensen, DePoint R Christensen, Mansoor Raza Mirza, Bente Lund, Johanna Mäenpää, Gunnar Kristensen

Research output: Contribution to journal › Article › Scientific › peer-review

9 Citations (Scopus)

Original language	English
Article number	937
Pages (from-to)	937
Journal	BMC Cancer
Volume	14
Issue number	1
DOIs	https://doi.org/10.1186/1471-2407-14-937
Publication status	Published - 2014
Publication type	A1 Journal article-refereed

Publication forum classification

Publication forum level 1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1471-2407-14-937

http://urn.fi/urn:nbn:fi:uta-201501131021

Cite this

Yun, W., Wang, Y., Herrstedt, J., Havsteen, H., Christensen, R. D., Christensen, D. R., Mirza, M. R., Lund, B., Mäenpää, J., & Kristensen, G. (2014). A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer. BMC Cancer, 14(1), 937. Article 937. https://doi.org/10.1186/1471-2407-14-937

@article{aab876cd8d514266b08a594cd9af0278,

title = "A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer",

author = "Wang Yun and Y Wang and Jorn Herrstedt and Hanne Havsteen and Christensen, {Rene DePoint} and Christensen, {DePoint R} and Mirza, {Mansoor Raza} and Bente Lund and Johanna M{\"a}enp{\"a}{\"a} and Gunnar Kristensen",

year = "2014",

doi = "10.1186/1471-2407-14-937",

language = "English",

volume = "14",

pages = "937",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "Springer Verlag",

number = "1",

}

Yun, W, Wang, Y, Herrstedt, J, Havsteen, H, Christensen, RD, Christensen, DR, Mirza, MR, Lund, B, Mäenpää, J & Kristensen, G 2014, 'A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer', BMC Cancer, vol. 14, no. 1, 937, pp. 937. https://doi.org/10.1186/1471-2407-14-937

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer. / Yun, Wang; Wang, Y; Herrstedt, Jorn et al.
In: BMC Cancer, Vol. 14, No. 1, 937, 2014, p. 937.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

AU - Yun, Wang

AU - Wang, Y

AU - Herrstedt, Jorn

AU - Havsteen, Hanne

AU - Christensen, Rene DePoint

AU - Christensen, DePoint R

AU - Mirza, Mansoor Raza

AU - Lund, Bente

AU - Mäenpää, Johanna

AU - Kristensen, Gunnar

PY - 2014

Y1 - 2014

U2 - 10.1186/1471-2407-14-937

DO - 10.1186/1471-2407-14-937

M3 - Article

SN - 1471-2407

VL - 14

SP - 937

JO - BMC Cancer

JF - BMC Cancer

IS - 1

M1 - 937

ER -

Yun W, Wang Y, Herrstedt J, Havsteen H, Christensen RD, Christensen DR et al. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer. BMC Cancer. 2014;14(1):937. 937. doi: 10.1186/1471-2407-14-937